Get the Stockscreener App
1.72
1.78%
+0.03
After Hours:
1.72
Scynexis Inc stock is currently priced at $1.72, with a 24-hour trading volume of 63,820.
It has seen a +1.78% increased in the last 24 hours and a +15.44% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.72 pivot point. If it approaches the $1.65 support level, significant changes may occur.
Previous Close:
$1.69
Open:
$1.66
24h Volume:
63,820
Market Cap:
$64.98M
Revenue:
$135.87M
Net Income/Loss:
$72.20M
P/E Ratio:
2.0476
EPS:
0.84
Net Cash Flow:
$45.09M
1W Performance:
+14.67%
1M Performance:
+15.44%
6M Performance:
-3.37%
1Y Performance:
-44.52%
1D Range:
$1.61
$1.74
52W Range:
$1.35
$3.87
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201 884 5485
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
GlobeNewswire Inc.
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewswire Inc.
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
GlobeNewswire Inc.
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
GlobeNewswire Inc.
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
GlobeNewswire Inc.
Scynexis Inc Stock (SCYX) Financials Data
Scynexis Inc (SCYX) Revenue 2024
SCYX reported a revenue (TTM) of $135.87 million for the quarter ending September 30, 2023, a +3,163% rise year-over-year.
Scynexis Inc (SCYX) Net Income 2024
SCYX net income (TTM) was $72.20 million for the quarter ending September 30, 2023, a +193.01% increase year-over-year.
Scynexis Inc (SCYX) Cash Flow 2024
SCYX recorded a free cash flow (TTM) of $45.09 million for the quarter ending September 30, 2023, a +154.20% increase year-over-year.
Scynexis Inc (SCYX) Earnings per Share 2024
SCYX earnings per share (TTM) was $1.42 for the quarter ending September 30, 2023, a +163.96% growth year-over-year.
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
0.08%
1.28%
Cap:
|
Volume (24h):